Our study demonstrated that CD22/CD19 dual‐targeting CAR‐T‐cell therapy could tremendously alleviate symptoms in 97% of patients, confirming previous publications highlighting CAR‐T‐cell therapy's benefits in ALL patients. Here, CD19 is linked to acute lymphoblastic leukemia.